



PSO2016

**5TH CONGRESS OF THE
PSORIASIS INTERNATIONAL NETWORK
SCIENTIFIC PROGRAM PROPOSED BY SOLAPSO**



DAY 1

09:00	REGISTRATION			
10:00	Round Table 1 Management of psoriasis by non-dermatologists: what you have to know?		Round Table 2 Late breaking abstract poster discussion	
11:00				
12:00	Satellite Symposia			
13:00	Networking Reception			
14:00	PLENARY SESSION 1 Psoriasis as a Systemic Inflammatory disease: Genetic and immunologic background			
15:00				
16:00	Break			
17:00	Workshops 1 Internal Medicine and Psoriasis	Workshops 2 Biosimilars in different scenarios (round table, regional differences)	Workshops 3 Treatments in PsA in adults and children	Workshops 4 Psychodermatology
18:00	Patient Associations Meeting (IFPA, EUROPSO, LATINAPSO)			
19:00				
20:00				

	Satellite Symposia		Plenary Session		Workshop
--	--------------------	--	-----------------	--	----------

DAY 2

09:00	Workshops 5 Topography: hair, nails, folders (3 round tables)	Workshops 6 Therapeutic targets in psoriasis	Workshops 7 Psoriasis yes or no (Interactive)	Workshops 8 Classical systemic treatments today: need for repositioning?
10:00	Break			
11:00	PLENARY SESSION 2 Psoriasis beyond T cells. Searching for other actors (Keratinocytes, mast cells, etc.)			
12:00	Satellite Symposia			
13:00	Satellite Symposia			
14:00	Break			
15:00	Workshops 9 Psoriasis: management in different moments (children, seniors, pregnancy, breast feeding)	Workshops 10 Topical treatments today	Workshops 11 Patients follow up with biologics and other treatments (How often? What to do?)	Workshops 12 Patient education. Tele dermatology
16:00	Break			
17:00	Satellite Symposia			
18:00	PIN National Representatives Meeting			
19:30				
	<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="display: flex; align-items: center;"> <div style="width: 15px; height: 15px; background-color: #008000; margin-right: 5px;"></div> Satellite Symposia </div> <div style="display: flex; align-items: center;"> <div style="width: 15px; height: 15px; background-color: #ff69b4; margin-right: 5px;"></div> Plenary Session </div> <div style="display: flex; align-items: center;"> <div style="width: 15px; height: 15px; background-color: #d8bfd8; margin-right: 5px;"></div> Workshop </div> </div>			

Scientific Programme

DAY 1

08.30 - 10:00:

Registration

10.00 - 11.30: Interactive Round Tables

Round Table 1

“Management of psoriasis by non-dermatologists: what you should know?”

Chairs: Louis Dubertret (France)

Craig Leonardi (USA) - Carolina Velásquez (Colombia) - Pablo Fernández-Peñas (Australia)

Round Table 2

“Late breaking abstract poster discussion”

PIN decision

11.30 - 13.00:

SATELLITE SYMPOSIA

13.00 - 14.00: NETWORKING RECEPTION

14:00 - 16:00

PLENARY SESSION 1

“Psoriasis as a Systemic Inflammatory disease: Genetic and immunologic background”

Chairs: Christopher EM Griffiths (UK) - Alice Gottlieb (USA) - Richard Langley (Canada)

1. Microbiome and Psoriasis: up to date. *K. Loser (Germany)*
2. The relationship between Psoriasis and the autoinflammatory diseases *Prof. Choi (Korea)*
3. New insights in Psoriasis genetics and epigenetics *Hervé Bachelez (France)*
4. Cytokine networks in Psoriasis and his comorbidities *Frank Nestlé (UK)*
5. Psoriasis and cardiovascular disease: do they share the same inflammatory pathways?
N. Mettha (USA)

16.00 - 16.30: BREAK

16:30 - 18:00:**WORKSHOPS**

W 1- Internal Medicine and Psoriasis

Chairs: Nikolai Tsankov (Bulgaria) - Carolina Cortez Correa (Colombia) - Mehmet Ali Gürer (Turkey)

1. Psoriasis and Cancer: is everything related to therapies? *Mona Stahle (Sweden)*
2. The association between Psoriasis and lung diseases *Peter van de Kerkhof (Netherlands)*
3. Ulcerative colitis, Crohn and Psoriasis: common physiopathological pathways? *Nancy Podoswa (Mexico)*
4. Metabolic syndrome and psoriasis. *Akihiko Asahina (Japan)*
5. Interdisciplinary management of erythrodermic and pustular psoriasis. *Tadashi Terui (Japan)*

W 2- Biosimilars in different scenarios (round table, regional differences)

Moderator: Diamant Thaci (Germany)

Margarita Velásquez Velásquez (Colombia) - Claudia de la Cruz (Chile) - SW Youn (Korea) - Muralidhar Rajgopal (India) - Lluís Puig (Spain)

W 3- Treatments in PsA in adults and children

Chairs: Irene Araya (Chile) - NI Kim (Korea) - Ignacio Dei Cas (Argentina)

1. Influence of cutaneous involvement in deciding how to treat psoriatic arthritis. *Alice Gottlieb (USA)*
2. Key topics in the management of psoriatic arthritis *Carlos Pineda (Mexico)*
3. Biologics in the treatment of psoriatic arthritis in children. Present and future. *Phillip Mease (USA)*
4. Treatment of psoriatic arthritis: traditional DMARDs and new therapies, approaches and recommendations *Toshiyuki Yamamoto (Japan)*

W 4- Psychodermatology

Chairs: Nora Poggio (Argentina) - Tarja Malkonen (Finland) - Robert Gniadecki (Denmark)

1. Stressful live events inducing psoriasis in childhood. *Christine Mandengue (Cameroon)*
2. The role of the dermatologist, psychiatrist and psychologist in the management of depression in psoriatic patients. *Adam Reich (Poland)*
3. The impact of biologics in depression: the evidence. *Gladys León Dorantes (Mexico)*
4. Stigmatization in psoriasis. *Jacek Szepietowski (Poland)*

18:00 - 20:00:**PATIENT ASSOCIATIONS MEETING (IFPA - Latinapso - Europso - Psorasia)**

1. Round Table about the global current patient situation.
2. Who Psoriasis Resolution. Its implementation in each region. Current status.
3. The future in psoriasis treatments. How the Associations must help.

To be by considered by IFPA.

DAY 2

8:30 - 10:00: WORKSHOPS

W 5- Topography: hair, nails, folders (3 round tables)

Three round tables with at least 2 experts in the field. One chairman who has to manage the presentation and the discussion. 30 minutes of clinical cases presentation and discussion of each theme. Question and answer

Chairs: Fernando Stengel (Argentina) - Nora Kogan (Argentina)

Hair: Lidia Rudnicka (Poland) - Carlos Carmona (Uruguay)

Facial and Fold: Jai Il Youn (Korea) - Luna Azulay (Brazil)

Nails: Antonella Tosti (Italy) - Luigi Naldi (Italy)

W 6- Therapeutic targets in psoriasis

Chairs: Graciela Pellerano (Argentina) - Michel de la Brassinne (Belgium) - Thomas Luger (Germany)

1. New topical targets *Matías Maskin (Argentina)*
2. The utility of proteomics to identify new therapeutic targets. *James Krueger (USA)*
3. Are PPARs a promising target to treat psoriasis? *Ricardo Romitti (Brazil)*
4. Small molecules: JAK inhibitors, Phosphodiesterase inhibitors and A3 adenosine receptor agonists. *Ulrich Mrowietz (Germany)*
5. Anti-IL 17 and Anti- IL 23: where we are and where we go? *Richard Langley (Canada)*

W 7- Psoriasis yes or no (Interactive)

Chairs: Hugo Schonenberber de Oliveira (Portugal) - Juan Raúl Castro Ayarza (Colombia) - Asja Prohic (Bosnia Herzegovina)

Clinical cases presentation of psoriasis differential diagnosis pathologies. The audience interacts using an electronic vote system.

W 8- Classical systemic treatments today: need for repositioning?

Chairs: Skaidra Valiukeviciene (Lithuania) - Tatiana Riveros (Chile) - Alexandra Espinal (Dominican Republic)

1. Methotrexate. *Richard Warren (UK)*
2. Cyclosporine. *Fernando Valenzuela (Chile)*
3. Acitretin. *Sunil Dogra (India)*
4. Fumarates. *Sandra Philipp (Germany)*

10.00 - 10.30: BREAK

10:30 - 12:00:

PLENARY SESSION

“Psoriasis beyond T cells. Searching for other actors (Keratinocytes, mast cells, etc)”

Chairs: Mona Stahle (Sweden) - George Stingl (Austria) - Peter Van der Kerkhof (Netherlands)

1. Keratinocytes and the impairment of cutaneous barrier in psoriasis. *Mark Lebwohl (USA)*
2. Keratinocytes and antimicrobial peptides in psoriasis. *Wolf-Henig Boehncki (Switzerland)*
3. Mast cells: witness or actors?. *Mayumi Komine (Japan)*
4. The role of neutrophils in psoriasis pathogenesis. *Kristian Reich (Germany)*
5. Dermal microenvironments in psoriasis plaque. *Jörg Christoph Prinz (Germany)*
6. Dendritic cells and the narrow line between tolerance and effective immunogenic response
Christopher EM Griffiths (UK)

12:30 - 14:00:

SATELLITE SYMPOSIA

12.00 - 14.30: BREAK

14:30 - 16:00:

WORKSHOPS

W9: Psoriasis: management in different moments (children, seniors, pregnancy, breast feeding)

Chairs: Leana Quintanilla (El Salvador) - Christina Antoniou (Greece) - Benny E. Wiryadi (Indonesia)

1. My patient is on systemic treatment and is pregnant! What do I have to do? *Andre Vicente Esteves de Carvalho (Brazil)*
2. Psoriasis treatment in the elderly: looking for comorbidities. *Yoshinori Umezawa (Japan)*
3. Children systemic therapies today: from the evidence to the clinical practice. *Cristine Bodemer (France)*
4. *Recommendations for patients under systemic treatment in case of traveling and surgery.*
Erika Páez (Venezuela)

W10: Topical treatments today)

Chairs: Mario Bittar (Argentina) - Emilija Manasievska (Macedonia) - Riad Mashal (Palestine)

1. Adherence: the first goal in topical treatments. *Norito Kato (Japan)*
2. Which is the role of topical therapy in nail psoriasis? *HJ Song (Korea)*
3. Corticosteroids with and without vitamin D. Still the first choice? *Carle Paul (France)*
4. Emerging topical drugs. *Luis Mazzuoccolo (Argentina)*

W11: Patients follow up with biologics and other treatments (How often? What to do?)

Chairs: Pravit Asawanonda (Thailand) - Pablo González (Argentina) - Tomaz Lunder (Slovenia)

1. Classical: *César González (Colombia)*
 - a. Methotrexate
 - b. Cyclosporine
 - c. Acitretin
2. Biologics: *Mario Amaya (Mexico)*
 - a. Anti TNF
 - b. Anti-IL 12-23
 - c. Anti-IL 17
3. Small molecules: *Craig Leonardi (USA)*
 - a. Apremilast
 - b. Tofacitinib
4. Combination therapies: *Alan Menter (USA)*

W12: Patient education and teledermatology

Chairs: Ezequiel Chouela (Argentina) - Aiman Alshami (Yemen) - Ljiljana Medenica (Serbia)

1. Working together to enhance adherence: patients, physicians and family members. *Jo Lambert (Belgium)*
2. The role of patient associations in community education. Avoiding discriminative behaviors. *Louis Dubertret (France)*
3. Worldwide education programs for psoriasis patients today. *Joo-Heung Lee (Korea)*
4. Which is the role and responsibilities of national authorities in patient education? *IFPA*

16.00 - 16.30: BREAK

16:30 - 18:00:
SATELLITE SYMPOSIA

18:00 - 19:30:
PIN NATIONAL REPRESENTATIVES MEETING

DAY 3

8:30 - 10:00: WORKSHOP

W13: Combined therapies and transition treatments: what we know?)

Chairs: Laith Akkash (Jordan) - Guadalupe Villanueva (Mexico) - Mohamed Cisse (Guinea)

1. Treatment goals and transition therapies: from guidelines to the real world. *Cristina Echeverría (Argentina)*
2. Treat to target in psoriasis and psoriatic arthritis. *Alexa Kimball (USA)*
3. Biosimilars: the risk of the transition. *Gilberto Castañeda (Mexico)*
4. Immunogenicity impact in treatment choice and transition therapies. *Kim Papp (Canada)*

W14: Biologics today and in the future)

Chairs: Adriana López Tello (Mexico) - Benny E. Wiryadi (Indonesia) - Andris Rubins (Latvia)

1. New insights in physiopathology and therapeutic targets. *Juan Manuel Carrascosa (Spain)*
2. The impact of biologics in psoriasis comorbidities. *Yves Poulin (Canada)*
3. New molecules in the pipeline. *Gabriel Magariños (Argentina)*
4. Health economics and biologics prescription: worldwide differences. *Hector Castellanos (Colombia)*

W15: Phototherapy

Chairs: Lajos Kemeny (Hungary) - Débora Kaplan (Argentina) - George-Sorin Tiplica (Romania)

1. The relation between phototherapy and skin cancer: how can we minimize the risks? *Hernán Correa (Chile)*
2. Target UVB phototherapy: indications and limitations. *Carlos Alvarez (Costa Rica)*
3. Home phototherapy: when and how? Is it safe? *Javier Ubogui (Argentina)*
4. Phototherapy in pediatric patients. *Joanna Narbutt (Poland)*

W16: Registries (regional differences, uncovered needs, communication networks, access to patients data)

Chairs: Benjamin Hidalgo (Costa Rica) - Rolland Gyulai (Hungary) - Aomar Ammar-Khodja (Algeria)

1. Goals and limitations in psoriasis registries, regional differences and regulatory issues. *Edgardo Chouela (Argentina)*
2. Patient associations, communication networks, psoriasis registries and the identification of the uncovered needs. *Pilar Valdez (Chile)*
3. The role of psoriasis registries in pharmacovigilance. *Angela Londoño (Colombia)*
4. It is possible to create a unique international registry? How to do it? *Nejib Doss (Tunisia)*

10.00 - 10.30: BREAK

10:30 - 12.30:

PLENARY SESSION

“Patient-oriented therapies” (personalized / custom-made)

Chairs: Eduardo Chouela (Argentina) - Craig Leonardi (USA) - Ulrich Mrowietz (Germany)

1. Genetic background and treatment response: personalized therapies? *George Stingl (Austria)*
2. Pharmacogenetics and pharmacogenomics in psoriasis: today and in the future. *Luis Puig (Spain)*
3. The influence of health resources in the access to medications: differences around the world. *Esteban Dauden (Spain)*
4. Could tailored therapies improve efficacy and safety issues? *Fernando Stengel (Argentina)*

12:30 - 14:00:

SATELLITE SYMPOSIA

14:00 - 15.30:

WORKSHOP

W17: Psoriasis in pediatrics)

Chairs: Carla Castro (Argentina) - Laura Alvarez Morales (Costa Rica) - Ligia Ramos (Honduras)

1. Epidemiology, diagnosis and prognosis. *R. Folster-Holst (Germany)*
2. Topical and systemic therapies for children today. *Alain Taib (France)*
3. How to manage long term side effects? *J. Harper (UK)*
4. Comorbidities and beyond. *Kelly Cordoro (USA)*

W18: Assessment tools in Pso and PsA)

Chairs: Simon Gusic (Argentina) - Lone Skov (Denmark) - Frank Behrens (Germany)

1. Introduction: Why I have to use assessment tools? *Lars Iversen (Denmark)*
2. PsA screening tools: PEST, PASE, TOPAS, CONTEST. *Luis Espinoza (USA)*
3. PsA disease assessment tools: ACR, PsARC, DAS28, BASDAI. *Rafael Valle Oñate (Colombia)*
4. Ps tools: PASI, PGA, BSA, DLQI. *Emad Elgamal (Egypt)*
5. Nails: NAPSI, Mnapsi. *Matthias Augustin (Germany)*

W19. Life quality and adherence to treatment (aspects related to physicians, family, friends, health policy)

Chairs: Jana Hercogova (Czech Republic) - Paula Bourren (Argentina) - Külli Kingp (Estonia)

1. Are there available tools good enough? What about cumulative life course impairment? *Martine Bagot (France)*
2. Coping strategies and the role of patient social network: tools to decrease life quality impact? *Kj Kim (Korea)*
3. Could early high effective therapies decrease the burden of the psoriatic disease? *Arnold Orange (Netherlands)*
4. Adherence: topical versus systemic treatments. *Giampiero Girolomoni (Italy)*

5. The role of physicians, family and social environment to increase adherence: creating new strategies
Prof. Romana Ceovic (Croatia)

W20: Phamacoeconomics and accessibility in the globalized world (regional differences, National health resources)

Chairs: Natalia Hernández (Colombia) - Omid Zargari (Iran) - Orestes Blanco (Cuba)

1. Access to medications in developing countries: are biosimilars a good choice? *Alur S. Kumar (India)*
2. The impact of guidelines to increase treatment access- *Alexander Nast (Germany)*
3. Cost effectiveness of high efficacy therapies in the treatment of severe psoriasis. *Zheng Min (China)*
4. Round table: representatives of Europe, Africa, Asia, Latin America and North America. Discussion of the regional access differences and the strategies to improve it. *Maria Lorna Frez (Philippines) - Fatimata Ly (Senegal) - Jean Paul Orthonne (France) - Minerva Gómez (Mexico)*

15.30 - 16.00: BREAK

16:00 - 18:00:

CLOSE PLENARY:

“Looking into the future”

Chairs: Nérida Raimondo (Argentina) - Louis Dubertreb (France) - Richard Warren (UK)

1- Research: *Frank Nestlé (UK) - James Kruger. (USA) - Phillips Mease (USA)*

2- Therapeutics: *Lluis Puig (Spain) - Kristian Reich (Germany) - Hervé Bachelez (France)*

E Posters

Optional:

- 1. Art gallery**